Table 1.
Demographic and pharmacokinetic data of patients with voriconazole treatment.
| Non-Carriers | Carriers | p Value | |
|---|---|---|---|
| Total patients | 22 | 11 | |
| Female | 10 | 7 | 0.465 |
| Male | 12 | 4 | |
| Age median (years) [IQR] | 7.5 [2.8–10.5] | 9 [7,8–10,5] | 0.135 |
| Weight median (kg) [IQR] | 23.5 [14,1–28,8] | 27.7 [25,0–32,0] | 0.0217 |
| Plasma concentrations measurement/patients median [IQR] | 1.5 [1–2,75] (n = 22) | 1.0 [1–2] (n = 11) | 0.615 |
| Dose median (mg/kg/day) [IQR] | 14.9 [10,0–16,0] (n = 81) | 14.6 [9,3–18,0] (n = 49) | 0.9 |
| All the dose-corrected plasma concentrations (µg/mL/mg/kg/day) mean [SD] | 0.046 [0,174] (n = 81) | 0.034 [0,07] (n = 49) | 0.011 |
| First voriconazole plasma concentration median (µg/mL) [IQR] | 1.12 [0,39–3,92] (n = 22) | 0.37 [0,16–1,19] (n = 11) | 0.054 |
| First dose-corrected voriconazole concentration median (µg/mL/mg/kg/day) [IQR] | 0.10 [0,02–0,34] (n = 22) | 0.029 [0,02–0,08] (n = 11) | 0.059 |
| Diagnosis | |||
| ALL | 13 | 6 | |
| AML | 5 | 5 | |
| Osteosarcoma | 1 | — | |
| Liver transplant | 1 | — | |
| Testicle tumor | 1 | — | |
| SCID | 1 | — | |
IQR, interquartile range; SD, Standard deviation; ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; SCID, Severe Combined Immunodeficiency.